A study of a new medicine (semorinemab) in patients with moderate Alzheimer's disease

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Neurodegenerative Disorder
Alzheimer's Disease (AD)

Results
Download
Print

Study results

LPS GN40040 Lauriet Final Results August 2024 US English (PDF, 0.1 MB)

LPS GN40040 Lauriet Final Results August 2024 Spain Spanish (PDF, 0.2 MB)

LPS GN40040 Lauriet Final Results August 2024 Poland Polish (PDF, 0.2 MB)

LPS GN40040 Lauriet Final Results August 2024 France French (PDF, 0.2 MB)

LPS GN40040 Lauriet Final Results August 2024 US Spanish (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A study of a new medicine (semorinemab) in patients with moderate Alzheimer's disease

Study results

LPS GN40040 Lauriet Final Results August 2024 US English (PDF, 0.1 MB)

LPS GN40040 Lauriet Final Results August 2024 Spain Spanish (PDF, 0.2 MB)

LPS GN40040 Lauriet Final Results August 2024 Poland Polish (PDF, 0.2 MB)

LPS GN40040 Lauriet Final Results August 2024 France French (PDF, 0.2 MB)

LPS GN40040 Lauriet Final Results August 2024 US Spanish (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A study of a new medicine (semorinemab) in patients with moderate Alzheimer's disease

For the latest version of this information please go to www.forpatients.roche.com